PharmaCielo Supports International Pain Congress

Medical cannabis company leads scientific and formal research on medicinal cannabis health effects

TORONTO, May 11, 2018 /CNW/ - Experts will debate and discuss the use of medical cannabis for the treatment of pain within the context of the 28th International Pain Congress May 10-12 in Medellín, Colombia, hosted by the Colombian Association for the Study of Pain (ACED) and its international partner, the International Association for the Study of Pain (IASP).

The important symposium, which gathers health professionals from different disciplines, including anesthesiologists, neurologists, experts in palliative care and oncologists, among others, has for the first time in its history dedicated a plenary session to address the issue of medical cannabis and its pharmacology, treatments, use and impact on the treatment of chronic pain and patient care.

Federico Cock-Correa, CEO of PharmaCielo Colombia Holdings, one of the companies sponsoring the event, comments, "We thank ACED for its interest and deepening investigation of the topic of medicinal cannabis. High-level events such as this contribute to demystifying and discussing with scientific rigor the beneficial properties that medicinal cannabis offers to human health."

The event was inaugurated by Luis Fernando Correa, Colombia's Deputy Minister of Public Health and Services, who has also highlighted issues like regulation to ensure security and informed access to medicinal cannabis for medical and scientific use.

About PharmaCielo

PharmaCielo Ltd. (the "Company") is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.

PharmaCielo Colombia Holdings S.A.S., a wholly owned subsidiary of PharmaCielo Ltd., is headquartered at the Company's Nursery and Propagation Center based in Rionegro, Colombia.

For further information:
www.PharmaCielo.com

This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "intends", "anticipates", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be achieved. These forward-looking statements are based on assumptions, including the ability for the Company and Ubiquo Telemedicina consummating the acquisition and executing their business plans, that management believes are reasonable in the circumstances, but the actual results, performance or achievements may be materially different from any future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including, but not limited to, risks associated with closing the acquisition of Ubiquo Telemedicina including failure to obtain necessary approvals, risks associated with early stage companies, risks associated with the regulation of cannabis and cannabinoid derivatives, and risks associated with operating in Colombia. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.

SOURCE PharmaCielo